A Novel Bioassay for the Activity Determination of Therapeutic Human Brain Natriuretic Peptide (BNP)

Lei Yu1, Chunming Rao1, Xinchang Shi1, Yonghong Li1, Kai Gao1, Xuguang Li2, Junzhi Wang1*

1 National Institute for the Control of Pharmaceutical and Biological Products, Beijing, People’s Republic of China, 2 Biologics and Genetic Therapies Directorate, Health Canada, Tunney’s Pasture, Ottawa, Canada

Abstract

**Background:** Recombinant human brain natriuretic peptide (rhBNP) is an important peptide-based therapeutic drug indicated for the treatment of acute heart failure. Accurate determination of the potency of therapeutic rhBNP is crucial for the safety and efficacy of the drug. The current bioassay involves use of rabbit aortic strips, with experiments being complicated and time-consuming and markedly variable in results. Animal-less methods with better precision and accuracy should be explored. We have therefore developed an alternative cell-based assay, which relies on the ability of BNP to induce cGMP production in HEK293 cells expressing BNP receptor guanylyl cyclase-A.

**Methodology/Principal Findings:** An alternative assay based on the measurement of BNP-induced cGMP production was developed. Specifically, the bioassay employs cells engineered to express BNP receptor guanylyl cyclase-A (GCA). Upon rhBNP stimulation, the levels of the second messenger cGMP in these cells drastically increased and subsequently secreted into culture supernatants. The quantity of cGMP, which corresponds to the rhBNP activity, was determined using a competitive ELISA developed by us. Compared with the traditional assay, the novel cell-based assay demonstrated better reproducibility and precision.

**Conclusion/Significance:** The optimized cell-based assay is much simpler, more rapid and precise compared with the traditional assay using animal tissues. To our knowledge, this is the first report on a novel and viable alternative assay for rhBNP potency analysis.

Citation: Yu L, Rao C, Shi X, Li Y, Gao K, et al. (2012) A Novel Bioassay for the Activity Determination of Therapeutic Human Brain Natriuretic Peptide (BNP). PLoS ONE 7(11): e49934. doi:10.1371/journal.pone.0049934

Copyright: © 2012 Yu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The current study was sponsored by Chinese governmental grants (2009ZX09307-001 and 2012ZX09304-010). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have the following interests: The work presented in this report is the subject of a pending patent filed by National Institutes for Food and Drug Control, Beijing, China. There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

* E-mail: wangjz@nicpbp.org.cn

Introduction

The natriuretic peptides (NPs) are a family of ring shaped vasoactive hormones with considerable sequence homology among themselves. Three mammalian NPs have been identified and characterized, including A-, B- and C-type [1,2]. Besides, several chimeric NPs have been reported [3,4]. The B-type natriuretic peptide (BNP), also called brain natriuretic peptide, a 32 amino acid polypeptide, is the most clinically potent type, which secretes from the ventricles in response to volume expansion and pressure overload [5]. It counterbalances actions of the renin-angiotensin-aldosterone and neurohormonal systems, and plays a central role in cardiovascular regulation [6]. There has been an explosion of clinical studies on the role and clinical application of BNP [7,8]. It is well known that BNP is a useful plasma marker in heart failure [9]. Besides, Recombinant human B-type natriuretic peptide (rhBNP) has been demonstrated to have beneficial vasodilatory, natriuretic, diuretic and neurohormonal effects. Moreover, the use of it as an effective therapeutic intervention was well established in patients with acute decompensated heart failure [10–12]. RhBNP was approved by the US Food and Drug Administration for the intravenous treatment of patients with acute decompensated congestive heart failure in 2001, and obtained a China national new drug certificate and production licenses in 2005.

The determination of biological potency plays a key role in the development, registration, and quality control of biological and biotechnology-derived products [13]. Accurate determination of the potency of therapeutic rhBNP is crucial to ensure the safety and efficacy of the drug. Its potency is currently determined by rabbit aortic strips test (RAST), for which the inhibitory activity of rhBNP on the tension of isolated aortic strips stimulated by phenylephrine is measured [14,15]. It is dependent on isolated tissue, which is known to be rough, laborious, time-consuming and extremely variable. Although the potency of BNP in plasma was generally determined by immunological methods clinically, these methods could not reflect the bioactivity of BNP [16]. Therefore, we need to explore another animal-free bioassay with better precision and accuracy.

With respect to the development of cell-based bioassay, various aspects of cell effects were introduced, including receptor phosphorylation, ion concentration, second messenger, reporter
gene expression [17], all of which are based on the pharmacological mechanism of drugs [18]. The biological action of BNP is mediated by its receptors, for which three have been reported, including natriuretic peptide receptor-A (NPR-A/GCA), B (NPR-B/GCB), and C (NPR-C). Natriuretic peptide receptor-A is the main receptor and mediates the endocrine effects of BNP, regulating arterial blood pressure and volume homeostasis in addition to local antihypertrophic actions in the heart [19,20]. It has an extracellular binding site, a transmembrane domain and an intracellular domain with a protein kinase-like region and a guanyl cyclase site [21,22]. Activated GCA receptor could catalyze the conversion of guanosine triphosphohate (GTP) to cyclic guanosine monophosphate (cGMP), a second messenger triggering potent vasodilatory actions. Specifically, cGMP activates cGMP-dependent protein kinase (PKG) to regulate various pathways including ion channels, substrate protein phosphorylation, translocation to the nucleus, and expression of related genes, all of which attribute to ultimate biological outcome[23–25]. Therefore, we hypothesized that quantification of cGMP could be correlated to rhBNP bioactivity.

In this report, a novel cell-based assay is reported employing cell lines stably expressing the GCA receptor. In response to rhBNP, the GCA receptor- laden cells produce drastically high levels of cGMP, which were precisely determined by competitive immunoassay. We show that the assay is reproducible, precise and robust, representing a viable alternative method to replace the animal tissue-based traditional assay.

Materials and Methods

Materials

HEK293 was purchased from ATCC. Plasmid pCMV6-ENTRY-GCA (sc125506) and anti-DDK mAb were purchased from OriGene. CGMP monoclonal antibody (ab363) was purchased from AbCam, and cGMP-HRP conjugate (M01058) was manufactured by GenScript. IBMX (15879) and phenylephrine were purchased from Sigma-Aldrich. GCA antibody (sc-157041) and Guanylin (sc-203066) were purchased from Santa-Cruz Protein G pre-coated microplates (15133) were purchased from Pierce. TMB (J64) and G418 sulfate (E859) were purchased from Amresco. RhBNP reference (0.1 mg/vial) was prepared by our department.

Cell Culture, Transfection and Colon Selection

Cell culture. Human embryonic kidney 293 cells were grown in DMEM-high glucose supplemented with 10% fetal calf serum, 100 U/mL penicillin, 100 mg/mL streptomycin sulfate and 0.25 mg/mL amphotericin B (Gibco). Cell passaging is achieved by detaching the cells in 0.25% Trypsin-EDTA (Gibco) and splitting the cells every 3 days.

Transfection. 6-well plate of cells (approximately 80% conment) were transfected with the plasmid pCMV6-ENTRY-GCA using Lipofectamine 2000 reagent (Invitrogen, #11668) according to the protocol. After cultured in growth media for 48 hours, cells were collected to next test.

Clone selection. HEK293 cells were transfected with pCMV6-ENTRY-GCA and grown in growth media for 48 hours. Then the growth media was replaced with selective media containing 200 μg/mL of the antibiotic G418. After growth in selective media for 4 weeks, resistant clones were subcloned by limited dilution and screened for the induction of cGMP generation by treatment of cells with gradient concentrations of rhBNP. The clone exhibiting the highest responsiveness to BNP was further characterized.

Western Blot

HEK293 cells transfected with pCMV6-ENTRY-GCA were rinsed twice with cold Phosphate Buffer Solution (PBS), then homogenized in RIPA cell lystate and centrifuged. The resulting supernatant (solvulized proteins) was subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 8% polyacrylamide gel. Proteins were transferred electrophoretically onto a polyvinylidene-difluoride (PVDF) membrane. After blocking in 5% skimmed milk, PVDF membranes were incubated with GCA or DDK antibody and then further incubated with HRP-conjugated anti-mouse secondary antibody. Proteins were visualized using the ECL Plus Western blot detection kit. Gel images were obtained with a ChemiDoc XRS imaging system.

Indirect Immunofluorescence Staining and Flow Cytometry

HEK293 and 293GCAC3 cells were harvested, rinsed once with PBS, and resuspended in 4% paraformaldehyde, incubating for 30 minutes at 4°C. Subsequently, fixed Cells were blocked in 1% BSA for 30 minutes at room temperature, and then incubated with DDK antibody for 60 minutes at 4°C. After rinsed once with PBS, the cells were incubated with FITC-labeled anti-mouse antibody for 60 minutes at 4°C. Then, the cells were fixed with 4% paraformaldehyde, and then the cell were permeabilized and blocked in 5% goat serum. The cells were then incubated with primary antibody overnight at 4°C, followed by incubation with Alexa Fluor 488-labeled secondary antibody for 1 hour at room temperature. Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI) for 5 minutes. The cells were then washed and mounted with Prolong Gold Antifade Mounting Media (Invitrogen). The fluorescence images were captured using a confocal microscope (Zeiss). The flow cytometry data were acquired using a FACSCalibur flow cytometer (Becton Dickinson) and analyzed with the CellQuest Pro software (Becton Dickinson).

293GCAC3-based Assay

293GCAC3 cells were plated in 96-well plates and treated with PBS, 5% FBS, or 10 ng/mL rhBNP. The cell culture supernatant was collected and analyzed for cGMP levels using a cGMP ELISA kit (Cayman Chemical). The data were normalized to the absorbance at 450 nm (OD450) and analyzed using Sigmaplot software (Systat Software).

Rabbit Aortic Strips Test

Aortic strips were isolated and prepared from New Zealand rabbits, and the strips were incubated with PBS, 5% FBS, or 10 ng/mL rhBNP for 16–18 hours. The aortic strips were treated with rhBNP and the tension was recorded at 30 minutes. The data were normalized to the absorbance at 450 nm (OD450) and analyzed using Sigmaplot software (Systat Software).

Antibody Neutralization Test

Anti-rhBNP serum was prepared from a New Zealand rabbit immunized by purified rhBNP and negative serum was prepared from control rabbit. At first, rhBNP was diluted to 1.25 μg/mL (working concentration is 250 ng/mL), the dosage which could stimulate the maximum amount of cGMP production. Then the
rhBNP dilution was incubated with a series of rhBNP anti-serum or negative serum diluted by 1:10² to 1:10⁷ at 37°C for 60 minutes. The mixtures were added to cell plate in the assay.

**Statistical Analyses**

Analyses of the data consisted of statistical models used to calculate EC₅₀ value as well as statistical techniques for method validation. In order to calculate the EC₅₀ values, dose response and linear range, we used the 4-PL model. Statistical techniques for method validation employed summary statistics such as mean, standard deviation, and relative standard deviation as well as statistical techniques such as T-test and confidence intervals. All statistical tests were carried out at a 5 % significance level. Analyses were carried out using sigmaplot11.0 for EC₅₀ calculations and GraphPad Prism 5 for method validation.

**Results**

1. **CGMP is Elevated in HEK293 Cells Expressing GCA upon Exposure to rhBNP**

As the initial step, we transiently transfected HEK293 cells with plasmid pCMV6-ENTRY-GCA and tested whether it could express exogenous GCA protein. To this end, we collected the transfected HEK 293 cells and detected the expression of GCA by western blot. The results indicated that exogenous GCA protein was over-expressed after transfection compared to the mock-transfected HEK293 cell control (Fig. 1A).

To compare the responsiveness of parental HEK293 cells and pCMV6-ENTRY-GCA transfected HEK293 cells, both of them were stimulated by rhBNP for 2 hours, followed by measuring the cGMP in culture supernatant by competitive ELISA. The results indicated that the pCMV6-ENTRY-GCA transfected HEK293 cells produced increased levels of cGMP in response to the ascending concentrations of rhBNP, while, clearly, the mock-transfected HEK293 failed to respond to rhBNP stimulation (Fig. 1B). Also noticeable is that the dose-response curve fitted 4-PL model, and demonstrating good linearity (R² of 0.94). As the cells transiently transfected with pCMV6-ENTRY-GCA demonstrated excellent response to rhBNP treatment, we next set out to develop a stable cell line overexpressing the receptor.

2. **Development of Stable rhBNP-responsive Cell Line**

HEK293 was transfected with pCMV6-ENTRY-GCA, and cultured in media containing 200 μg/mL G418 for 4 weeks. Positive clones selected by G418 were subcloned to get monoclone cell lines by limited dilution. As shown in Figure S1, two clones (clone 3 and clone4) were found to produce high levels of cGMP in response to rhBNP treatment, with Clone 3 exhibiting stronger reactivity. This clone was then designated as 293GCAC3, which was later further characterized.

We next confirmed the expression of exogenous GCA in the selected cells by flow cytometry. DDK antibody was used as detection antibody. As the DDK tag is in the intracellular region of GCA, cells were treated with 0.1% triton X-100 to permeabilize the cell membrane. The results indicated that almost all of the 293GCAC3 cells over-expressed DDK-tagged GCA (Fig. 2).

3. **Optimization of the Assay**

To improve the signal of the assay, we introduced protein G, an immunoglobulin-binding protein expressed in group C and G

---

**Figure 1. Transfection and detection of the response to rhBNP.** Panel A. GCA over-expression in transiently transfected cells. Western blot was used to detect the expression of GCA. The primary antibodies are GCA antibody and DDK antibody; GAPDH serves as internal control. Panel B. HEK293 cells were transiently transfected with pCMV6-ENTRY-GCA and stimulated with different concentrations of rhBNP for 2 hours. Then cGMP was quantified by competitive ELISA. Each point represents the mean of 3 replicates.

doi:10.1371/journal.pone.0049934.g001
DDK antibody

Specimen 003-Tube 293-P1

parental 293

293GCAC3
Streptococcal bacteria, which has binding capacity to the Fc region of antibody [26]. The microtiter plates pre-coated with protein G would bind cGMP antibody more efficiently than non-coated microtiter plates. As shown in Figure S2A, the use of protein-G to capture the cGMP-antibody in the assay resulted in stronger signal (OD_{450} values) than assay where antibody was directly absorbed to the ELISA plate, and 1:6000 dilution of cGMP antibody with protein G-coated is sufficient for the assay.

We also tested the incubation time for the cells to be exposed to rhBNP. Figure S2B showed that following stimulation for 1.5 hours, the mount of cGMP had reached peak value. Therefore, all subsequent experiments were conducted using the 1.5 hours incubation time. Table 1 summarized the optimized conditions used in all subsequent experiments.

4. Specificity of the Assay

To study the specificity of the assay, we tested another peptide guanylin, which is known to activate guanylate cyclase and stimulate cGMP production [27]. As the receptor of guanylin is guanylate cyclase-C (GC-C) [28], it is theoretically not expected to stimulate the increase of cGMP, and would represent a meaningful control to investigate the specificity of the assay.

To this end, 293GCAC3 cells were treated with rhBNP and guanylin dilutions respectively. As shown in Figure 3A, the levels of cGMP increased in response to rhBNP treatment, but not following guanylin treatment, revealing that the assay is specific for rhBNP.

The specificity of the assay was further investigated by determining whether rhBNP antibody could block rhBNP-induced cGMP. To this end, rhBNP were pre-incubated with specific antisera and then analyzed its activity in the assay. As shown in Figure 3B, if not pre-incubated with the antisera, rhBNP increased cGMP production, yet its stimulatory effects on cGMP production were substantially attenuated after pre-incubation with the antisera for 1 hour; also of note is that the negative serum control showed no effects on rhBNP’s effects on cGMP production as expected.

5. Comparison of Cell-based Test with Rabbit Aortic Strips Test (RAST)

Therapeutic rhBNP references were tested by 293GCAC3-based assay and RAST for five separate runs to compare sensitivity, precision and variability. As it shown in Figure 4, the results showed that no significant difference in EC_{50} values was found between two assays (unpaired t test, p = 0.8582), but the relative standard deviation (RSD) values between the two assays were drastic. For the new assay, the RSD was just 12.5%, with the 95% CI being 5.387 ng/mL to 7.359 ng/mL while RAST has RSD of 65.9%, with the 95% CI falling between 1.098 ng/mL to 10.98 ng/mL. Other items including curve fitness, inter-assay RSD, intra-assay RSD, and linear detection range were also compared as listed in Table 2. As shown in Table 2, the new assay is better than the traditional assay in curve fitness, intra- and inter-assay variability. These results suggest that 293GCAC3-based assay is more precise and better suited for future routine analyses of rhBNP products.

6. The Stability of the Cell Lines

To test the stability of 293GCAC3 cells, cells at three different stages (passage # 5, 18, 65) were evaluated by testing their responsiveness to rhBNP stimulation. The comparison experiments involved 3 replicates for each dose. As shown in Table 3, the results revealed no significant difference among the EC_{50} means from cells derived from three different passages (One-way analysis of variance, p = 0.3780); the RSD values are found to be below 20%. Collectively these results further confirm that cell-based assay is robust.

Discussion

Recombinant human brain natriuretic peptide(rhBNP) have been prescribed in the last few decades for the treatment of decompensated acute heart failure [11]. Accurate determination of the potency of therapeutic rhBNP is crucial for the safety and efficacy of the drug. The potency of this peptide drug is currently determined by rabbit aortic strips test (RAST), in which the inhibitory activity of rhBNPs on tension of rabbit aortic strip stimulated by phenylephrine is measured [15,29]. RAST is known to be laborious and time-consuming, with poor reproducibility and isolation of fresh aortic strip from sacrificed rabbit. Numerous attempts have been made over the last years to develop alternative assays aimed at reduced use of animals and improved precision and robustness.

Given the well-characterized pathways activated by rhBNP, quantification of cGMP in cells exposed to rhBNP has been explored as attractive alternative assay. Indeed, several types of cGMP-involved assays for rhBNPs have been reported in recent years, including the measurement of cGMP in HUVEC (human umbilical vein endothelial cells) or PC12 cells by radioimmunoassay [22,30,31]. However, both HUVEC and PC12 cells are not stable in culture as one would expect, given that HUVEC are primary cells and PC12 tends to differentiate. Moreover, the measurement of intracellular cGMP is very tedious, requiring preparation of cell lysates and determination of cGMP concentration depending on cGMP standard curve by radioimmunoassay. Furthermore, data generated from these aforementioned systems are limited in terms of reproducibility, precision and

Table 1. Optimized parameters for the 293GCAC3-based bioassay.

| Parameters                      | Optimized values                        |
|---------------------------------|-----------------------------------------|
| Cell Number (per well)          | 1.8 × 10^4                               |
| Cell Culture Time               | 16–20 hours                              |
| Linear Range of rhBNP Dose      | 500 ng/mL–0.05 ng/mL                     |
| rhBNP Stimulation Time          | 1.5 hours                                |
| cGMP-HRP Dilution Rate          | 1:1000                                   |
| cGMP Antibody Dilution Rate     | 1:6000 (with pre-coated protein G)       |

Various parameters of the assay were optimized, including cell number, cell culture time, cGMP-HRP dilution rate and so on as listed in Table 1.

doi:10.1371/journal.pone.0049934.t001
accuracy in addition to appropriate comparison with the traditional RAST. The disadvantages associated with these assays prompted us to develop a stable cell-based assay for the potency determination of therapeutic rhBNP, based on studies on GC-A receptor using HEK293 cells [32]. There are several advantages in our assay: 1) a single high-responsiveness clone was isolated with stability confirmed even in culture for 65 passages; 2) the operation is drastically simplified with detection of cGMP in culture supernatants and use of non-radioactive materials in immunoassays in a high through-put manner; 3) the new assay has demonstrated defined specificity, greater precision and reproducibility in validation studies compared with RAST, for which no

![Figure 3. Specificity of the assay. Panel A. Effect of guanylin on 293GCAC3. Guanylin is also a little peptide which could stimulate the increase of cGMP by binding GC-C. The starting concentration of rhBNP and guanylin was 2 µg/mL, serially diluted by 4 times, with the effects of these two peptides on cGMP production tested simultaneously. The data showed the guanylin had no effect on 293GCAC3 compared with rhBNP. Each point illustrates the mean of 3 replicates. Panel B. The effects of neutralizing antibody on rhBNP-induced cGMP production. rhBNP (0.5 µg/mL) was pre-incubated with rhBNP anti-serum or negative serum of serial dilutions (1:107–1:102) at 37°C for 60 minutes. Afterwards, the mixture was analyzed for its ability of stimulating cGMP production. The results indicated that rhBNP-induced cGMP production was inhibited by the neutralizing antibody in a dose-responsive fashion. Each point illustrates the mean of 3 replicates. doi:10.1371/journal.pone.0049934.g003](image)

Figure 4. Comparison between 293GCAC3-based test and rabbit aortic strips test (RAST). The new 293GCAC3 assay and traditional RAST assay were conducted in five separate runs to compare sensitivity, precision and variability. The EC50 values determined by two assays were found to be similar (unpaired t test, p = 0.8582). However, For the new assay, the RSD was just 13.1%, with the 95% CI being 5.387 ng/mL to 7.359 ng/mL, while for RAST, RSD was 65.9%, with the 95% CI falling between 1.098 ng/mL to 10.98 ng/mL. doi:10.1371/journal.pone.0049934.g004

| Table 2. Comparison between 293GCAC3-based test and rabbit aortic strips test (RAST). |
|---------------------------------|----------------|----------------|
| Curve Fitness(R²)              | >0.95          | >0.80          |
| Intra-assay RSD                | 6.680%         | 19.09%         |
| Inter-assay RSD                | 17.45%         | 54.58%         |
| Sensitivity (ng/mL, 95% CI of EC₅₀) | 5.387–7.359   | 1.098–10.98    |
| Linear Detection Range (ng/mL) | 1.172–43.35    | 1.221–41.02    |

RHBNP references were tested by both 293GCAC3-based assay and RAST. Various items including curve fitness, intra-assay RSD, inter-assay RSD, 95% CI of EC₅₀ and linear detection range were compared between the two assays. The 293GCAC3-assay is better than RAST assay in curve fitness, intra- and inter-assay variability. doi:10.1371/journal.pone.0049934.t002
previous studies have reported. Given the superiority of the new assay over RAST and advantage of elimination of use of animals, it could be envisaged that such robust cell-based assays could be increasingly used in critical analyses of human therapeutics. As the scope of this study is focused on the development of an alternative assay for the potency determination of the pharmaceutical rhBNP to replace the traditional animal-dependent assay (RAST), we did not attempt to explore its application to the measurement of endogenous BNP activities in patients with cardiac conditions. While it would be of significant interest to employ this current assay to monitor endogenous activities, given that various forms of BNP in patients with cardiac condition [16], the assay would require additional strenuous validation studies including the assay specificity using patient samples collected at various clinical stages. This is a future endeavor which we are considering with the aim at expanding the assay to clinical application.

**References**

1. Dries DL (2007) Relevance of molecular forms of brain natriuretic peptide for natriuretic peptide research. Hypertension 49: 971–973.
2. Wu ZJ, Xia W, Zhang FR, Liu Y (2012) Recent advances in natriuretic peptide family genes and cardiovascular diseases. Yi Chuan 34: 127–133.
3. Chen BY, Chen JK, Zhou MY, Zhang DL, Sun JS, et al. (2011) AC-NP: a novel chimeric peptide with natriuretic and vasorelaxing actions. PlaS One 6: e20477.
4. Liu O, Hundle BK, McCormick DJ, Kurkulas PY, Burnett JC Jr. (2008) Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol 52: 60–68.
5. Cauiliez B, Berthe MC, Lavoinne A (2005) Brain natriuretic peptide: physiological, biological and clinical aspects. Ann Biol Clin (Paris) 63: 15–25.
6. Misone KS, Philo JS, Arakawa T, Ogata GM, Qin Y, et al. (2011) Structure, signaling mechanism and regulation of the natriuretic peptide receptor guanylate cyclase. FERS J 278: 1818–1829.
7. Mills RM, Hobbs RE, Young JB (2002) “BNP” for heart failure: role of neprilysin in cardiovascular therapeutics. Congest Heart Fail 8: 270–273.
8. Gassing N, Bieschke B, Sigl D, Aichler M, et al. (2012) Neprilysin in therapy for decompensated heart failure. Eur J Clin Pharmacol 68: 223–230.
9. Geotz JP (2012) B-type natriuretic peptide: from posttranslational processing to clinical measurement. Clin Chem 58: 83–91.
10. Nygren S, Feldman DS, Trupp R, Abraham WT (2004) Neprilysin for the treatment of congestive heart failure. Expert Opin Pharmacother 5: 901–907.
11. Keating GM, Goa KL (2005) Neprilysin: a review of its use in acute decompensated heart failure. Drugs 63: 47–70.
12. Colbert M, Green MH (2005) Neprilysin (Natriuretic): a new treatment for acute decompensated congestive heart failure. Crit Care Nurse 26: 40–44.
13. Moring TS, Singer R, Ambrose MR, Hauck WW (2009) Biological Potency Assays are Key to Assessing Product Consistency. BioPharm International 22.
14. Silberbach M, Roberts CT Jr. (2001) Natriuretic peptide signalling: molecular and cellular pathways to growth regulation. Cell Signal 13: 221–231.
15. Sun Z, Chen J, Yao H, Liu L, Wang J, et al. (2005) Use of Sup danl derived mini-mim as a fusion partner for production of recombinant human brain natriuretic peptide in Escherichia coli. Protein Expr Purif 33: 26–32.

**Supporting Information**

**Figure S1** Colone selection. Uncloned cells selected by G418 and 4 monoclones subsequently obtained by limited dilution were tested to verify their responsiveness to rhBNP. Clone 1 and 2 hardly responded to rhBNP, and clone 3 had the strongest responsibility to rhBNP.

**Figure S2** Optimization of the assay. Panel A. Optimization of competitive ELISA. Protein G-coated microtiter plates were introduced. The figure shows that the use of protein-G to capture the cGMP-antibody in the assay resulted in stronger signal (OD450 values) than assay where antibody was directly absorbed to the ELISA plate. Panel B. Determination of optimal rhBNP stimulation time. 0.5, 1, 1.5 and 2 hours were tested. Following rhBNP stimulation for 1.5 hours, the level of cGMP reached the maximum, suggesting that incubation beyond 1.5 hr of the cells with rhBNP was unnecessary.

**Acknowledgments**

We thank Dr. WenHong Fan and Ningsheng Shao for technical assistance and consultations, Lan Wang, Hua Bi, Xi Qin, Dening Pei, Lei Tao and Zhihao Fu for helpful discussions.

**Author Contributions**

Conceived and designed the experiments: JW. Performed the experiments: LY. Contributed reagents/materials/analysis tools: CR. Wrote the paper: LY. Participated in the experiments (Rabbit aortic strips test): XS. Guided the experiments: YL. KG. Data analysis (Indirect immunofluorescence staining and flow cytometry): YL. Data analysis (competitive ELISA): KG. Guided the writing and revised the manuscript: XL.

---

**Table 3.** Test of the stability of the cell lines.

|   | P5 | P18 | P65 |
|---|---|---|---|
| EC50 (ng/mL) | 6.075 | 5.040 | 6.625 |
| Mean (ng/mL) | 6.745 | 6.295 | 5.690 |
| SD | 0.451 | 1.150 | 0.822 |
| RSD | 6.7 % | 18.3 % | 14.4 % |

293GAC3 cells at three different stages (passage # 5, 18, 65) were tested in optimized condition, which involved 3 replicates for each dose. EC50, mean, SD (standard deviation) and RSD (relative standard deviation) values of them were listed in Table 3. No significant difference existed among the EC50 means of three stages (One-way analysis of variance, p = 0.3788).

---

**References**

1. Dries DL (2007) Relevance of molecular forms of brain natriuretic peptide for natriuretic peptide research. Adv Clin Chem 58: 45–48.
2. Larocque L, Blaauw Y, Dirris A, Wang J, et al. (2011) Bioactivity determination of native and variant forms of therapeutic interferons. J Biomed Biotechnol 2011: 174615.
3. Mire-Sluis AR (2001) Progress in the use of biological assays during the development of biotechnology products. Pharm Res 18: 1239–1246.
4. Kushiato I, Tokudome T, Teraso T, Garbers DL, Nakao K, et al. (2009) Natriuretic Peptide Signaling via Guanylyl Cyclase (GC)-A: An Endogenous Protective Mechanism of the Heart. Curr Cardio Rev 5: 45–51.
5. Pandey KN (2011) Guanylyl cyclase / atrial natriuretic peptide receptor-A: role in the pathophysiology of cardiovascular regulation. Can J Physiol Pharmacol 89: 557–573.
6. Misone KS (2002) Natriuretic peptide receptor: structure and signaling. Mol Cell Biochem 230: 49–60.
7. Tremblay J, Desjardins R, Hurst D, Gutzowska J, Hamlet P (2002) Biochemistry and physiology of the natriuretic peptide receptor guanylyl cyclases. Mol Cell Biochem 230: 31–47.
8. Currie MG, Fok KF, Kato J, Moore RJ, Hamra FK, et al. (1992) Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci U S A 89: 947–951.
28. Spreca A, Simonetti S, Rambotti MG (2000) Atrial natriuretic peptide and guanylin-activated guanylate cyclase isoforms in human sweat glands. Histochem J 32: 725–731.

29. Rao C-M, Wang J-Z, Zhao Y, Han C-M, Guo Y, et al. (2002) Study of the Requirements and Methods for Quality Control of Recombinant Human Brain Natriuretic Peptide. Chinese Journal of Pharmaceutical Analysis: 346–349.

30. Rautureau Y, Gowers I, Wheeler-Jones CP, Baxter GF (2010) C-type natriuretic peptide regulation of guanosine-3,5-cyclic monophosphate production in human endothelial cells. Auton Autacoid Pharmacol 30: 185–192.

31. Pan S, Chen HH, Dickey DM, Boerrigter G, Lee C, et al. (2009) Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide. Proc Natl Acad Sci U S A 106: 11292–11297.

32. Dickey DM, Barbieri KA, McGuirk CM, Potter LR (2010) Arg13 of B-type natriuretic Peptide reciprocally modulates binding to guanylyl cyclase but not clearance receptors. Mol Pharmacol 78: 431–435.